The diagnostics of colorectal cancer

Colorectal cancer (CRC) is one of the most frequent human malignant neoplasms. CRC has an estimated incidence of more than 1,000,000 new cases annually worldwide. Approximately one out of three people who develop CRC dies from the disease. Furthermore, CRC often affects inhabitants of industrialized countries in comparison to less developed countries. Several markers of colon cancer, including CEA, CA-19-9, TPS, TAG-72 and lysosomal hydrolases, have been identified and are now being adopted in routine clinical practice. Increased values of these markers are often the first signal of recurrence or metastases, which is useful in prediction and prognosis of clinical outcome of patients with CRC. Determination of the activity of lysosomal exoglycosidases in body fluids may bring some hope of improving diagnosis of colorectal cancer. However, it has to be remembered that currently the most effective diagnostic method of CRC is endoscopy.

[1]  Daniel F Hayes,et al.  ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  A. Milewska,et al.  Lysosomal exoglycosidases and cathepsin D in colon adenocarcinoma. , 2012, Polskie Archiwum Medycyny Wewnetrznej.

[3]  K. Zwierz,et al.  Lysosomal exoglycosidases in serum and urine of patients with colon adenocarcinoma. , 2008, Hepato-gastroenterology.

[4]  C. Emiliani,et al.  Human lysosomal α-D-mannosidase regulation in promyelocytic leukaemia cells. , 2011, Bioscience reports.

[5]  Douglas K Rex,et al.  Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer. , 2012, Gastroenterology.

[6]  P. Maisonneuve,et al.  Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps. , 2008, Gastroenterology.

[7]  M. Marzola,et al.  18 F-FDG PET/CT may detect early response to Imatinib mesylate in GISTs with exon 11 mutation: case report and critical review of literature , 2013 .

[8]  A. Massaro,et al.  Additional Value of FDG-PET/CT in Management of “Solitary” Liver Metastases: Preliminary Results of a Prospective Multicenter Study , 2010, Molecular Imaging and Biology.

[9]  K. Zwierz,et al.  N-acetyl-beta-D-hexosaminidase and its isoenzymes A and B in blood serum and urine, as a potential colon cancer markers. , 2009, Hepato-gastroenterology.

[10]  K. Zwierz,et al.  Carbohydrate Markers in Colon Carcinoma , 2009, Disease markers.

[11]  H. Lenz,et al.  Molecular Markers in the Treatment of Metastatic Colorectal Cancer , 2010, Cancer journal.

[12]  M. Houshmand,et al.  Mitochondrial haplogroup analysis in colorectal cancer: Identification of a high-risk population , 2008 .

[13]  M. Resnick,et al.  Application of molecular techniques in the diagnosis, prognosis and management of patients with colorectal cancer: a practical approach. , 2012, Human pathology.

[14]  Charles J. Kahi,et al.  Screening and surveillance for colorectal cancer: state of the art. , 2013, Gastrointestinal endoscopy.

[15]  J. Schachter,et al.  Initial TPS serum level as an indicator of relapse and survival in colorectal cancer. , 1998, Anticancer research.

[16]  Perry J Pickhardt,et al.  Screening and Surveillance for the Early Detection of Colorectal Cancer and Adenomatous Polyps, 2008: A Joint Guideline from the American Cancer Society, the US Multi‐Society Task Force on Colorectal Cancer, and the American College of Radiology * † , 2008, CA: a cancer journal for clinicians.

[17]  Mukesh Verma,et al.  Epigenetic Biomarkers in Colorectal Cancer , 2016, Molecular Diagnosis & Therapy.

[18]  C. Albrecht,et al.  β-Glucosidase activity in fetal bovine serum renders the plant glucoside, hypoxoside, cytotoxic toward B16-F10-BL-6 mouse melanoma cells , 1994, In Vitro Cellular & Developmental Biology - Animal.

[19]  R. Bast,et al.  Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. , 1996, Journal of the National Cancer Institute.

[20]  Bharati Bapat,et al.  Epigenetic biomarkers in colorectal cancer diagnostics , 2012, Expert review of molecular diagnostics.

[21]  D. Ahlquist.  Molecular detection of colorectal neoplasia. , 2010, Gastroenterology.

[22]  D. Rubello,et al.  The role of dual-time combined 18-fluorodeoxyglucose positron emission tomography and computed tomography in the staging and restaging workup of locally advanced rectal cancer, treated with preoperative chemoradiation therapy and radical surgery. , 2009, International journal of radiation oncology, biology, physics.

[23]  Takahiro Tanaka,et al.  Biomarkers for Colorectal Cancer , 2010, International journal of molecular sciences.

[24]  M. Gunter,et al.  Obesity and colorectal cancer: epidemiology, mechanisms and candidate genes. , 2006, The Journal of nutritional biochemistry.

[25]  K. Zwierz,et al.  Role of N-acetyl-β-d-hexosaminidase in cholesteatoma tissue , 2007 .

[26]  A. Massaro,et al.  Colorectal cancer: prognostic role of 18F-FDG-PET/CT , 2012, Abdominal Imaging.

[27]  K. Zwierz,et al.  Role of N-acetyl-beta-d-hexosaminidase in cholesteatoma tissue. , 2007, Acta biochimica Polonica.

[28]  Elena Bellan,et al.  Fifteen different 18F-FDG PET/CT qualitative and quantitative parameters investigated as pathological response predictors of locally advanced rectal cancer treated by neoadjuvant chemoradiation therapy , 2013, European Journal of Nuclear Medicine and Molecular Imaging.